Overview
Melanotan II (MT-II) is a cyclic synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s as part of a program to find a safe method to induce melanogenesis for photoprotection. Unlike the linear peptide α-MSH, MT-II is cyclic and metabolically more stable. MT-II activates multiple melanocortin receptors (MC1R through MC5R), producing broader effects than the more selective compounds derived from it (Melanotan I for pigmentation; PT-141/bremelanotide for sexual function). Its non-selectivity produces a spectrum of effects studied across pigmentation, sexual arousal, appetite suppression, and inflammation research.
Mechanism
MT-II is a non-selective melanocortin receptor agonist. At MC1R (melanocytes), it stimulates eumelanin production and skin darkening. At MC4R (hypothalamus), it suppresses appetite and activates pro-sexual CNS pathways. At MC3R, it modulates energy homeostasis. At MC5R, it influences exocrine gland secretion. The combination of these effects — particularly tanning + sexual function + appetite suppression — made it the original "Barbie drug" of research interest before regulatory actions increased scrutiny.
Research Areas
Side Effects (Preclinical)
- – Nausea (very common)
- – Spontaneous erections in male subjects
- – Hyperpigmentation (can be permanent with chronic use)
- – Facial flushing
- – Darkening of existing moles — warrants monitoring
Cautions
- – For research use only — significant regulatory scrutiny in multiple jurisdictions
- – Mole darkening and new nevus formation have been reported; melanoma risk not fully characterized
- – Non-selective receptor activation makes side effect profile less predictable than PT-141
- – UK and multiple EU countries have issued safety warnings about unlicensed use
What the research shows
The University of Arizona program (Dorr et al., 1996) established proof-of-concept for MT-II induced melanogenesis in human subjects, showing dose-dependent skin darkening. The same program serendipitously documented the sexual function effects that led to the PT-141 program.
MT-II’s non-selectivity is both its research interest and its caution flag. The mole darkening / nevus activation potential has made dermatologists and regulatory bodies particularly cautious, and multiple countries have issued specific warnings about unlicensed MT-II products.
References
- Melanotan II, a melanocortin agonist, activates penile erection — Wessells H et al. (1996)
- Efficacy of melanotan II for skin pigmentation in humans — Dorr RT et al. (1996)